Gemtuzumab ozogamicin for acute myeloid leukemia
Gemtuzumab ozogamicin for acute myeloid leukemia
复制标题
DOI：
10.1182/blood-2017-09-797712
复制
发表时间：
2017-11-30
期刊：
影响因子：
20.3
通讯作者：
Bernstein, Irwin D.
中科院分区：
文献类型：
--
作者：
Appelbaum, Frederick R.;Bernstein, Irwin D.
2017年9月1日，美国食品药品监督管理局（FDA）批准吉妥珠单抗（GO）用于治疗新诊断的CD 33（+）急性髓性白血病成人患者和年龄≥ 2岁的CD 33（+）急性髓性白血病复发或对初始治疗无反应的患者。这标志着GO漫长而不寻常的故事的新篇章，GO是FDA批准用于人类的第一个抗体药物缀合物。
On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33(+) acute myeloid leukemia and for patients aged >= 2 years with CD33(+) acute myeloid leukemia who have experienced a relapse or who have not responded to initial treatment. This signals a new chapter in the long and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FDA.